TITLE OF THE INVENTION 6-AZAINDOLE COMPOUND AS ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE BACKGROUND OF THE INVENTION The gonadotropin-releasing hormone (GnRH), also referred to as luteinizing hormone-releasing hormone (LHRH), is a decapeptide that plays a key role in human reproduction. The hormone is released from the hypothalamus and acts on the pituitary gland to stimulate the biosynthesis and secretion of luteinizing hormone (LH) and follicle- stimulating hormone (FSH). LH released from the pituitary gland is primarily responsible for the regulation of gonadal steroid production in both sexes, whereas FSH regulates spermatogenesis in males and follicular development in females. GnRH agonists and antagonists have proven effective in the treatment of certain conditions which require inhibition of LH/FSH release. In particular, GnRH-based therapies have proven effective in the treatment of endometriosis, uterine fibroids, polycystic ovarian disease, precocious puberty and several gonadal steroid- dependent neoplasia, most notably cancers of the prostate, breast and ovary. GnRH agonists and antagonists have also been utilized in various assiste fertilization techniques and have been investigated as a potential contraceptive in both men and women. They have also shown possible utility in the treatment of pituitary gonadotrophe adenomas, sleep disorders such as sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hyperplasia, hirsutism, as an adjunct to growth hormone therapy in growth hormone deficient children, and in murine models of lupus. The compound of the invention may also be used in combination with bisphosphonates (bisphosphonic acids) and other agents, such as growth hormone secretagogues, for the treatment and the prevention of disturbances of calcium, phosphate and bone metabolism, in particular, for the prevention of bone loss during therapy with the GnRH antagonist, and in combination with estrogens, progesterones, antiestrogens, antiprogestins and/or androgens for the prevention or

treatment of bone loss or hypogonadal symptoms such as hot flashes during therapy with the GnRH antagonist.

Additionally, a compound of the present invention may be co-administered with a 5a-reductase 2 inhibitor, such as finasteride or epristeride; a 5a-reductase 1 inhibitor such as 4,7b-dimethyl-4-aza-5a- cholestan-3-one, 3-oxo-4-aza-4,7b-dimethyl-16b- (4-chlorophenoxy)-5a- androstane, and 3-oxo-4-aza-4,7b-dimethyl-16b- (phenoxy)-5a-androstane as disclosed in WO 93/23420 and WO 95/11254; dual inhibitors of 5a- reductase 1 and 5a-reductase 2 such as 3-oxo-4-aza-17b- (2,5-trifluoro- methylphenyl-carbamoyl)-5a-androstane as disclosed in WO 95/07927; antiandrogens such as flutamide, casodex and cyproterone acetate, and alpha-1 blockers such as prazosin, terazosin, doxazosin, tamsulosin, and alfuzosin.

Further, a compound of the present invention may be used in combination with growth hormone, growth hormone releasing hormone or growth hormone secretagogues, to delay puberty in growth hormone deficient children, which will allow them to continue to gain height before fusion of the epiphyses and cessation of growth at puberty.

Further, a compound of the present invention may be used in combination or co-administered with a compound having luteinizing hormone releasing activity such as a peptide or natural hormone or analog thereof. Such peptide compound include leuprorelin, gonadorelin, buserelin, triptorelin, goserelin, nafarelin, histrelin, deslorelin, meterlin and recirelin.

Additionally, a compound of the present invention may be used as described in U. S. Patent No. 5,824,286 which discloses the administration of peptide GnRH antagonists such as Antide and azaline B to premenopausal women to enhance the readability of mammographic film relative to a mammogram effected in the absence of the administration.

Current GnRH antagonists are GnRH-like decapeptides which are generally administered intravenously or subcutaneously presumably because of negligible oral activity. These have amino acid substitutions usually at positions one, two, three, six and ten.

Non-peptide GnRH antagonists offer the possible avantage of oral adminstration. Non-peptide GnRH antagonists have been described in European Application 0 219 292 and in De, B. et al., J. Med. Chem., 32,2036-2038 (1989), in WO 95/28405, WO 95/29900 and EP 0679642 all to Takeda Chemical Industries, Ltd.

Substituted indoles known in the art include those described in the following patents and patent applications. US Patent No. 5,030,640 discloses alpha-heterocyclic ethanol aminoalkyl indoles which are potent ß-agonists. US Patent No. 4,544,663 discloses indolamine derivatives which are allegedly useful as male anti-fertility agents. WO 90/05721 discloses alpha-amino-indole-3-acetic acids useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents. French patent 2,181,559 discloses indole derivatives with sedative, neuroleptic, analgesic, hypotensive, antiserotonin and adrenolytic activity. Belgian patent 879381 discloses 3-aminoalkyl-lH-indole-5-thioamide and carboxamide derivatives as cardiovascular agents used to treat hypertension, Raynaud's disease and migraine. U. S. Patent Nos.

5,756,507,5, 780, 437 and 5,849,764 also disclose substituted arylindoles as non-peptide antagonists of GnRH.

SUMMARY OF THE INVENTION The present invention relates to compound which are non-peptide antagonists of GnRH which can be used to treat a variety of sex-hormone related conditions in men and women, to methods for their preparation, and to methods and pharmaceutical compositions containing said compound for use in mammals.

Because of their activity as antagonists of the hormone GnRH, the compound of the present invention are useful to treat a variety of sex-hormone related conditions in both men and women.

These conditions include endometriosis, uterine fibroids, polycystic ovarian disease, hirsutism, precocious puberty, gonadal steroid-dependent neoplasias such as cancers of the prostate, breast and ovary, gonadotrophe pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual

syndrome and benign prostatic hypertophy. They are also useful as an adjunct to treatment of growth hormone deficiency and short stature, and for the treatment of systemic lupus erythematosis. Further, the compound of the invention may be useful in i7t viíro fertilization and as contraceptives. The compound may also be useful in combination with androgens, estrogens, progesterones, antiestrogens and antiprogestogens for the treatment of endometriosis, fibroids and in contraception. They may also be useful in combination with testosterone or other androgens or antiprogestogens in men as a contraceptive. The compound may also be used in combination with an angiotensin-converting enzyme inhibitor such as Enalapril or Captopril, an angiotensin II-receptor antagonist such as Losartan or a renin inhibitor for the treatment of uterine fibroids.

Additionally, the compound of the invention may also be used in combination with bisphosphonates (bisphosphonic acids) and other agents, for the treatment and the prevention of disturbances of calcium, phosphate and bone metabolism, in particular, for the prevention of bone loss during therapy with the GnRH antagonist, and in combination with estrogens, progesterones and/or androgens for the prevention or treatment of bone loss or hypogonadal symptoms such as hot flashes during therapy with the GnRH antagonist.

Additionally, a compound of the present invention may be co-administered with a 5a-reductase 2 inhibitor, such as finasteride or ide; a 5a-reductase 1 inhibitor such as 4, 7b-dimethyl-4-aza-5a- cholestan-3-one,3-oxo-4-aza-4,7b-dimethyl-16b- (4-chlorophenoxy)-5a- androstane, and 3-oxo-4-aza-4,7b-dimethyl-16b- (phenoxy)-5a-androstane as disclosed in WO 93/23420 and WO 95/11254; dual inhibitors of 5a- reductase 1 and 5a-reductase 2 such as 3-oxo-4-aza-17b- (2,5-trifluoro- methylphenyl-carbamoyl)-5a-androstane as disclosed in WO 95/07927; antiandrogens such as flutamide, casodex and cyproterone acetate, and alpha-1 blockers such as prazosin, terazosin, doxazosin, tamsulosin, and alfuzosin.

Further, a compound of the present invention may be used in combination with growth hormone, growth hormone releasing hormone or growth hormone secretagogues, to delay puberty in growth

hormone deficient children, which will allow them to continue to gain height before fusion of the epiphyses and cessation of growth at puberty.

Further, a compound of the present invention may be used in combination or co-administered with a compound having luteinizing hormone releasing activity such as a peptide or natural hormone or analog thereof. Such peptide compound include leuprorelin, gonadorelin, buserelin, triptorelin, goserelin, nafarelin, histrelin, deslorelin, meterlin and recirelin.

Additionally, a compound of the present invention may be used as described in U. S. Patent No. 5,824,286 which discloses the administration of peptide GnRH antagonists such as Antide and azaline B to premenopausal women to enhance the readability of mammographic film relative to a mammogram effected in the absence of the administration.

DETAILED DESCRIPTION OF THE INVENTION The present invention relates to compound of the general formula wherein A is Cl-C6 alkyl, substituted Cl-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, C3-C6 alkenyl, substituted C3-C6 alkenyl, C3-C6 alkynyl, substituted C3-C6 alkynyl, Cl-C6 alkoxy, or Co-Cs alkyl-S (O) n-Co-Cs alkyl, Co-Cs alkyl- O-Co-Cs alkyl, C0-C5 alkyl-NR18-C0-C5 alkyl where R18 and the Co-Cs alkyl can be joined to form a ring, or a single bond;

Ro is hydrogen, Cl-C6 alkyl, substituted Cl-C6 alkyl, wherein the substituents are as defined below; aryl, substituted aryl, aralkyl or substituted aralkyl, wherein the substituents are as defined for R3, R4 and R5; Rl is

the nitrogen atoms contained in the RI heteroaromatic rings may exist either as drawn or, when chemically allowed, in their oxidized (N#O)state; R2 is hydrogen, Cl-C6 alkyl, substituted C1-C6 alkyl, aralkyl, substituted aralkyl, aryl, substituted aryl, alkyl-OR11, orC(NR11R12)NH;C1-C6(NR11R12),C1-C6(CONR11R12) R2 and A taken together form a ring of 5-7 atoms;

R3, R4 and R5 are independently hydrogen, Cl-C6 alkyl, substituted Cl-C6 alkyl, C2-C6 alkenyl, substituted C2-C6 alkenyl, CN, nitro, Cl-C3 perfluoroalkyl, Cl-C3 perfluoroalkoxy, aryl, substituted aryl, aralkyl, substituted aralkyl, R110 (CH2) p-, -(CH2)pS(O)nR17,R11C(O)O(CH2)p-,R11OC(O)(CH2)p-, -(CH2) pC (O) NR11R12 or halogen; wherein R17 is hydrogen, Cl-C6 alkyl, Cl-C3 perfluoroalkyl, aryl or substituted aryl; R3 and R4 taken together form a carbocyclic ring of 3-7 carbon atoms or a heterocyclic ring containing 1-3 heteroatoms selected from N, 0 and S; R6 is hydrogen, Cl-C6 alkyl, substituted Cl-C6 alkyl, aryl, substituted aryl, Cl-C3 perfluoroalkyl, CN, N02, halogen, NR21C(O)NR20R21orR11O(CH2)p-,NR21C(O)R20, SOnR20; R7 is hydrogen, Cl-C6 alkyl, or substituted Cl-C6 alkyl, unless X is hydrogen or halogen, then R7 is absent; R8 is C (O) OR20, C (O) NR20R21, NR20R21, C (O) R20, NR20S(O)2R21,NR21C(O)R20,NR21C(O)NR20R21, OC(O)NR20R21,OR20,NR21S(O)2NR20R21,OC(O)R20, SOnR20, S (O) nNR20R21, a heterocyclic ring or bicyclic heterocyclic ring with from 1 to 4 heteroatoms selected from N, O or S which can be optionally substituted by R3, R4 and R5, C1-C6 alkyl or substituted Cl-C6 alkyl; or R7 and R8 taken together form a heterocyclic ring containing one or more heteroatoms selected from N, O or S which can be optionally substituted by R3, R4 and R5; Rg and Rga are independently hydrogen, Cl-C6 alkyl, substituted Cl-C6 alkyl; aryl or substituted aryl, aralkyl or substituted aralkyl when m70; or Rg and Rga taken together form a carbocyclic ring of 3-7 atoms or when M70;

Rg and A taken together form a heterocyclic ring containing 3-7 carbon atoms and one or more heteroatoms when m :0; or RIO and R10a are independently hydrogen, Cl-C6 alkyl, substituted Cl-C6 alkyl, aryl, substituted aryl, aralkyl or substituted aralkyl; or RIO and R10a taken together form a carbocyclic ring of 3-7 atoms or Rg and RIO taken together form a carbocyclic ring of 3-7 carbon atoms or a heterocyclic ring containing one or more heteroatoms when m#0;or Rg and R2 taken together form a heterocyclic ring containing 3-7 carbon atoms and one or more heteroatoms when m#0 ; or RIO and R2 taken together form a heterocyclic ring containing 3-7 carbon atoms and one or more heteroatoms; Rlo and A taken together form a heterocyclic ring containing 3-7 carbon atoms and one or more heteroatoms; or R1l and R12 are independently hydrogen, Cl-C6 alkyl, substituted Cl-C6 alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, a carbocyclic ring of 3-7 atoms or a substituted carbocyclic ring containing 3-7 atoms; R1l and R12 taken together can form an optionally substituted ring of 3-7 atoms; R13 is hydrogen, OH, NR7R8, NRIIS02 (Cl-C6 alkyl), NR11SO2 (substituted Cl-C6 alkyl), NRIIS02 (aryl), NR11SO2 (substituted aryl), NRIIS02 (Cl-C3 perfluoroalkyl); S02NR11 (CI-C6 alkyl), SO2NR11 (substituted Cl-C6 alkyl), SO2NR11(aryl), SO2NR11(C1-C3aryl), perfluoroalkyl); SO2NR11 (C (O) C1-C6 alkyl); S02NR11 (C (O)- substituted Cl-C6 alkyl); S02NR11 (C (O)-aryl) ; S(O)n(C1-C6alkyl);S(O)nSO2NR11(C(O)-substitutedaryl); (substituted C1-C6 alkyl), S (O) n (aryl), S (O) n (substituted aryl), Cl-C3 perfluoroalkyl, Cl-C3 perfluoroalkoxy, Cl-C6 alkoxy, substituted Cl-C6 alkoxy, COOH, halogen, N02 or CN;

R14 and R15 are independently hydrogen, Cl-C6 alkyl, substituted Cl-C6 alkyl, C2-C6 alkenyl, substituted C2-C6 alkenyl, CN, nitro, Cl-. C3 perfluoroalkyl, Cl-C3 perfluoroalkoxy, aryl, substituted aryl, aralkyl, substituted aralkyl, R110 (CH2) p-, R11C (O) O (CH2) p-, R11OC (O) (CH2) p-, -(CH2)pS(O)nR17, -(CH2) pC (O) NR11R12 or halogen; wherein R17 is hydrogen, Cl-C6 alkyl, Cl-C3 perfluoroalkyl, aryl or substituted aryl; R18 is hydrogen, Cl-C6 alkyl, substituted Cl-C6 alkyl, C (O) OR11, S(O)nR11;C(O)NR11R12,C(O)R11, R1g is either the definition of R13 or R14; R20 and R21 are independently hydrogen, Cl-C6 alkyl, substituted Cl-C6 alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, a carbocyclic ring of 3-7 atoms, a substituted carbocyclic ring containing 3-7 atoms, a heterocyclic ring or bicyclic heterocyclic ring with from 1 to 4 heteroatoms selected from N, O or S which can be optionally substituted by R3, R4 and R5, C1-C6-alkyl substituted by a heterocyclic ring or bicyclic heterocyclic ring with from 1 to 4 heteroatoms selected from N, O or S which can be optionally substituted by R3, R4 and R5; R20 and R21 taken together can form an optionally substituted ring of 3-7 atoms; X is N, O, S (O) n, C (O), (CR11R12) p, a single bond to Rg, C2-C6 alkenyl, substituted C2-C6 alkenyl, C2-C6 alkynyl, or substituted C2-C6 alkynyl; when X is O, S (O) n, C (O), or CR11R12 only R8 is possible; Z is 0, S or NR11; in is 0-3; n is 0-2; p is 0-4; and the alkyl, cycloalkyl, alkenyl and alkynyl substituents are selected from C1-C6 alkyl, C3-C7 cycloalkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, hydroxy, oxo, cyano, Cl-C6 alkoxy, fluoro, C (O) OR11 aryl Cl-C3 alkoxy, substituted aryl

Cl-C3 alkoxy, and the aryl substituents are as defined for R3, R4 and R5; or a pharmaceutically acceptable addition salt and/or hydrate thereof, or where applicable, a geometric or optical isomer or racemic mixture thereof.

Preferred substituents when R20 and R21 are taken together include 7-aza-bicyclo [2.2.1] heptane and 2-aza-bicyclo [2.2.2] octane.

Unless otherwise stated or indicated, the following definitions shall apply throughout the specification and claims.

When any variable (e. g., aryl, heterocycle, RI, etc.) occurs more than one time in any constituent or in formula I, its definition on each occurrence is independent of its definition at every other occurrence.

Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compound.

The term"alkyl"is intended to include both branche- and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, e. g., methyl (Me), ethyl (Et), propyl, butyl, pentyl, hexyl, heptyl, octyl, nonanyl, decyl, undecyl, dodecyl, and the isomers thereof such as isopropyl (1-pur), isobutyl (i-Bu), sec-butyl (s-Bu), tert-butyl (t-Bu), isopentane, isohexane, etc.

The term"aryl"includes phenyl and naphthyl. In a preferred embodiment, aryl is phenyl.

The term"halogen"or"halo"is intended to include fluorine, chlorine, bromine and iodine.

The term"heterocycle"or"heterocyclic ring"is defined by all non-aromatic, heterocyclic rings of 3-7 atoms containing 1-3 heteroatoms selected from N, O, and S, such as oxirane, oxetane, tetrahydrofuran, tetrahydropyran, pyrrolidine, piperidine, tetrahydropyridine, tetrahydro- pyrimidine, tetrahydrothiophene, tetrahydrothiopyran, morpholine, hydantoin, valerolactam, pyrrolidinone, and the like.

As used herein, the term"composition"is intended to encompass a product comprising the specified ingredients in the specified

amonts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amonts.

In addition, it is well known to those skilled in the art that many of the foregoing heterocyclic groups can exist in more than one tautomeric form. It is intended that all such tautomers be included within the ambit of this invention.

The optical isomeric forms, that is mixtures of enantiomers, e. g., racemates, or diastereomers as well as individual enantiomers or diastereomers of the instant compound are included. These individual enantiomers are commonly designated according to the optical rotation they effect by the symbols (+) and (-), (L) and (D), (1) and (d) or combinations thereof. These isomers may also be designated according to their absolut spatial configuration by (S) and (R), which stands for siniser and rectus, respectively.

The individual optical isomers may be prepared using conventional resolution procedures, e. g., treatment with an appropriate optically active acid, separating the diastereomers and then recovering the desired isomer. In addition, the individual optical isomers may be prepared by asymmetric synthesis.

Additionally, a given chemical formula or name shall encompass pharmaceutically acceptable addition salts thereof and solvates thereof, such as hydrates.

The compound of the present invention, while effective themselves, mav be formulated and administered in the form of their pharmaceutically acceptable addition salts for purposes of stability, convenience of crystallization, increased solubility and other desirable properties.

The compound of the present invention may be administered in the form of pharmaceutically acceptable salts. The term "pharmaceutically acceptable salt"is intended to include all acceptable salts. Examples of acid salts are hydrochloric, nitric, sulfuric, phosphoric, formic, acetic, trifluoroacetic, propionic, maleic, succinic, malonic, methanesulfonic, benzenesulfonic and the like which can be used as a

dosage form for modifying the solubility or hydrolysis characteristics or can be used in sustained release or prodrug formulations. Depending on the particular functionality of the compound of the present invention, pharmaceutically acceptable salts of the compound of this invention include those formed from cations such as sodium, potassium, aluminum, calcium, lithium, magnesium, zinc, and from bases such as ammonia, ethylenediamine, N-methyl-glutamine, lysine, arginine, ornithine, choline, N, N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaïne, N-benzylphenethylamine, diethylamine, piperazine, tris (hydroxymethyl) aminomethane, and tetramethylammonium hydroxide. These salts may be prepared by standard procedures, e. g. by reacting a free acid with a suitable organic or inorganic base, or alternatively by reacting a free base with a suitable organic or inorganic acid.

Also, in the case of an acid (-COOH) or alcohol group being present, pharmaceutically acceptable esters can be employed, e. g. methyl, ethyl, butyl, acetate, maleate, pivaloyloxymethyl, and the like, and those esters known in the art for modifying solubility or hydrolysis characteristics for use as sustained release or prodrug formulations.

The compound of the present invention may have chiral centers other than those centers whose stereochemistry is depicted in formula I, and therefore may occur as racemates, racemic mixtures and as individual enantiomers or diastereomers, with all such isomeric forms being included in the present invention as well as mixtures thereof. Furthermore, some of the crystalline forms for compound of the present invention may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compound of the instant invention may form solvates with water or common organic solvents. Such solvates are encompassed within the scope of this invention.

The compound of the invention are prepared according to the following rection schemes. All of the substituents are as defined above unless indicated otherwise.

Rection Scheme A R8 Pd (dppCl2CHzCIz R. I (CR9Rya)OPG LiCI Na2C03, Ro toa DMF, heat NHz Z 2a Z = H R5 1 2b Z = Et3Si 2c Z R Rs s Ra R /Q\ R.CR9R9a m R5 R4 RoRaoa I RoRoa and NPG ft Fi Rs H (CRcR9alm 3b Z = EtSi 3cZ= 4aZ=H 4c Z Rs R 3 R5 R4 R5 R4

A preferred method for the synthesis of the substituted tryptamines described in this invention utilizes a palladium-catalyzed cross coupling rection as a key step as shown in Scheme A. This 6- azaindole synthesis involves the rection of a suitably functionalized 3-amino-4-iodopyridine (1) with substituted acetylenes such as 2 in the presence of a base like sodium carbonate, lithium chloride, and a palladium catalyst such as (dppf)PdCl2#CH2Cl2. The rection is conducted in an inert organic solvent such as dimethylformamide at elevated temperatures, for instance at 100°C, and the rection is conducted for a period of about 30 minutes to about 24 hours. A standard workup and isolation affords the substituted isomeric indole derivatives 3 and 4, and the isomer of general formula 3 is the preferred isomer. The acetylene utilized in this rection may be a terminal acetylene (2a) or be optionally substituted on the terminal carbon atom with a substituent Z (2b, 2c).

The substituent abbreviated PGI indicates an alcohol protecting group such as a benzyl ether, tert-butyl ether or the like. The nature of the Z substituent determines the distribution of the 6-azaindole isomers (3

and 4) produced in the rection. For example, if the substituent Z on the acetylene is a hydrogen atom then the isomer 4a is the major product of the rection. When the substituent Z is chosen to be a substituted silyl group such as trimethylsilyl, triethylsilyl (as shown), or the like, then isomer 3b is formed almost exclusively. When Z is a substituted aryl group, then both isomers 3c and 4c may be formed and the product mixture is separated using chromatographic or crystallization techniques to afford the individual isomers.

If the synthesis is conducted with a silyl-substituted acetylene 2b to produce a silyl-substituted 6-azaindole 3b, then the silyl group is next converted to an aryl or substituted aryl group of general formula 3c using the rections described later in Scheme E. The 2- arylsubstituted 6-azaindole derivatives 3c formed either directly from arylacetylenes (2c) as shown in Scheme A or from 2-trialkylsilyl-6- azaindoles using the method of Scheme E are then further elaborated as described below to produce the novel 6-azaindole derivatives described in this invention.

Rection Scheme B Scheme B illustrates the preparation of substituted 3-

amino-4-iodopyridines (1) which are utilized in the 6-azaindole synthesis described in Scheme A. Substituted 3-nitropyridine derivatives such as 5 are useful starting materials for the preparation of 3-amino-4- iodopyridines (1). The 3-nitropyridines (5) bearing the desired substituents can in turn be prepared by the nitration of a pyridine derivative, by a nucleophilic aromatic substitution rection from a suitable halogenated nitropyridine or by other methods known in the chemical literature. The nitro substituent of a 3-nitropyridine is readily reduced to the required 3-amino group using a variety of methods such as catalytic hydrogenation and the resulting 3-amino group can then serve as a directing group for the subsequent introduction of an iodine at the 4 position of the pyridine. To facilitate the introduction of the iodine atom the 3-amino group is first converted to a good ortho-directing substituent such as a pivalamide (7). This is achieved by reacting the 3-amino- pyridine 6 with pivaloyl chloride in the presence of an amine base like triethylamine in a suitable inert solvent followed by a standard workup and isolation. The resulting pivalamide 7 is then subjected to ortho- lithiation by treatment with a strong organolithium base such as tert- butyl lithium in the presence of a N, N, N', N'-tetramethylethylene- diamine. The ortho-lithiation is conducted in an inert solvent such as tetrahydrofuran at low temperature, typically-78°C, and the 4-lithiated derivative is the predominant regioisomer formed. Once the lithiation rection is complete the rection mixture is then treated with an iodinating reagent like iodine or iodine monochloride in a comptable solvent such as tetrahydrofuran and then allowed to warm to room temperature. Workup and product purification affords the 4-iodopyridine derivative 8 which in the final step is converted to the substituted 3- amino-4-iodopyridines of general formula 1 by removal of the ortho- directing group. In the case illustrated in rection Scheme B where a pivaloyl group was chosen as the ortho-directing group it may be removed by hydrolysis under acidic conditions such as treatment with sulfuric acid at anelevated temperature.

Rection Scheme C

Acetylenic compound of general structure 2 are prepared using one of several methods depending upon the choice of the desired substituents. When the substituents R9, R9a, R10 and Rio, are selected to be hydrogen or lower alkyl groups, compound of formula 2 may be prepared from known acetylenic alcools such as 3-butyn-1-ol> 4-pentyn- 2-ol or similar acetylenic alcools reporte in the chemical literature.

The conversion of acetylenic alcools of general formula 10 to acetylene derivatives of general formula 2 is shown in Scheme C. For clarity the hydroxyl protecting group (PG1) illustrated in Scheme C is exemplified as an O-benzyl ether. Thus, rection of 10 with O-benzyl-2,2,2-trichloro- * iodate in the presence of a catalytic amount of a strong acid such as trifluoromethanesulfonic acid and in a suitable inert organic solvent like carbon tetrachloride at room temperature affords after 2 to 24 hours

the protected acetylenic alcohol 2a. Compound of formula 2a may in turn be converted to acetylenes (2b) of general formula 2 wherein Z is a trialkylsilyl group by deprotonation of the acetylene with a base such as n-butyllithium in an inert organic solvent like tetrahydrofuran followed by rection with a trialkylsilyl chloride such as triethylchlorosilane. The deprotonation and silylation rections are generally conducted at low temperatures, for instance between about-78°C and room temperature, and after standard workup and purification a silylacetylene of formula 2b is obtained.

As previously stated, acetylenes of general formula 2c wherein Z is an aryl or substituted aryl group, are also useful in the 6- azaindole synthesis illustrated in Scheme A. Arylacetylenes 2c may be prepared using a coupling rection of cuprous acetylides derived from acetylenic alcools of formula 2a with various aryl halides or aryl triflates (11). Such coupling rections produce aryl acetylenes of general formula 12 as shown at the bottom of Scheme C. These rections are generally carried out in a basic organic solvent like triethylamine at elevated temperatures, typically between about 60°C and about 120°C, and the coupling rection is catalyzed by copper (I) salts such as cuprous iodide and a palladium catalyst such as palladium acetate in combination with triphenylphosphine. The hydroxyl group of the arylacetylenes of general formula 12 can be protected with a suitable protecting group such as the O-benzyl ether group shown in Scheme C, to afford an arylacetylene (2c) of general formula 2 wherein Z is an aryl or substituted aryl group. It is also recognized that in some cases it may be preferable to reverse the order of the steps illustrated in Scheme C. For instance, acetylenic alcools (7) may be subjected to silylation or arylation prior to the hydroxyl group protection step.

Rection Scheme D

Another useful approach for the preparation of acetylenic compound of general formula 2a employs an ethynylation rection sequence of aldehydes of general formula 16 as shown in Scheme D. The aldehydes (16) used in the ethynylation sequence may be prepared using various methods known in organic synthesis starting with hydroxyesters of general formula 13, from protected hydroxyesters of formula 14, or from alcools related to the mono-hydroxyl protected diols of formula 15. The choice of preferred starting material depends upon the nature of the substituents Rg, Rsa Rlo, and Rloa selected. Scheme D illustrates this strategy begining with the generalized hydroxy ester 13. Protection of the hydroxyl group of 13, for instance as the O-benzylether shown, affords a protected hydroxy ester of formula 14. The ester group of compound of formula 14 can then be converted to an aldehyde of formula 16 either directly using a reagent like diisobutylaluminum hydride in a solvent like toluene, or through a two step process. In the two step process, reduction of the ester group with a reagent such as lithium aluminum hydride in tetrahydrofuran affords alcools of formula 15 which are then subjected

to reoxidation, for instance using a Swern-Moffatt oxidation, to afford the desired aldehydes of formula 16.

The ethynylation of aldehydes of formula 16 is accomplished in two steps. First, aldehydes (16) are reacted with carbon tetrabromide and triphenylphosphine in an inert organic solvent like dichloromethane to produce the dibromo olefins of formula 17. Next, the dibromo olefins (17) are treated with two equivalents of a strong base such as m-butyllithium in tetrahydrofuran at low temperature, for instance at about-78°C. The strong base induces dehydrohalogenation and metal- halogen exchange to afford lithium acetylides which upon quenching and workup afford acetylenes of general formula 2a. Alternatively, the intermediate lithium acetylides formed in the rection may be treated with a trialkylsilyl chloride, such as triethylchlorosilane, to afford silylacetylenes of general formula 2b.

Rection Scheme E R8 R8 R,CR9R9a)W PG R1.CR9R9a)PG 1 R6 H, R H N I SiEt3 H t ICl, AgBF4, 6 3b MeOH-THF, 0PC 17 R8 (H) zB Ry-CR9R9anPG 17 + I'J R3 N\o ioa v R5 R4 (dppf) PdCl,-CHcl,, R6 H TR3 toluene-EtOH-2M aq. Na, CO ;, 3c 80pC Rs Ra The conversion of 2-silyl-substituted 6-azaindoles of general formula 3b to 2-aryl-substituted 6-azaindoles of general formula 3c mazer be accomplished in two steps as shown in Scheme E. The first step is a halodesilylation rection which converts silyl-substituted 6-azaindoles

of formula 3b into 2-halo-6-azaindoles of general formula 18. Scheme E illustrates this process using iodine monochloride so that the product obtained is a 2-iodoindole of general formula 18. Silver tetrafluoroborate is also employed in this example to increase the reactivity of the halogenating ragent. It is possible to effect the halodesilylation rection with other electrophilic halogenating reagents such as N- bromosuccinimide in dichloromethane which affords a 2-bromo-6- azaindole derivative. Both 2-bromo and 2-iodo-6-azaindoles of formula 18 are useful in the subsequent step.

The second step is a palladium-catalyzed cross coupling rection of the 2-halo-6-azaindole 18 with a suitable aryl or substituted aryl organometallic reagent 19. Scheme E illustrates this process with an aryl or substituted arylboronic acid as the organometallic ragent, however, other organometallic reagents known to participate in palladium-catalyzed cross-coupling rections such as arylboronic esters or arylstannanes may also be employed. In the example, a 2-iodo-6- azaindole of general formula 18 is coupled with a generalized boronic acid (19) using a catalyst such as [1,1'-bis (diphenylphosphino) ferrocene] dichloropalladium (II) complex with dichloromethane (show), tetrakis (triphenylphosphine)-palladium (0) or the like. The rection is usually conducted at temperatures between room temperature and about 100°C, for instance at about 80°C. This palladium catalyzed cross-coupling rection may be effected using various combinations of palladium catalysts and solvent compositions known in organic chemistry, and the selection of the conditions is made depending upon the type of organometallic reagent (19) used and the identity of the substituent groups in the two starting materials. When the organometallic reagent is a boronic acid or boronate ester then a preferred solvent mixture consists of toluene, ethanol and an aqueous solution of a base like cesium or sodium carbonate. If instead the organometallic reagent 19 is an arylstannane, then no additional base is required, and a polar aprotic solvent such as tetrahydrofuran or dimethylformamide is employed.

Rection Scheme F R8 R8 R.CRnRea) nPG Protect R. WR9R9a) nPG7 r Rlo Rloa 6-azaindole P R10R1Oa Rs H, \ R3 or introduce Rr, TR3 Ro substituent PG2 3c Rs R4 19 Rs R4 Deprotect 18 PPh,, DEAD alcohol R (CR9Ra) nOH Zn (N3), 2pyr> imidazole, CH, CI' 2 @\ rt, 1-24 h 20 Rs R4 20 RS RQ Ru R8 (CRgRa) nN3 RCR9R9am 1% Pd/C, H,, loa ETOH, rt 1-12 h"loa 21 Rs R4 22 Rs R4 Zon 21 Z 5v RQ 22 Sv Ra

The next stage of the synthesis of the novel 6-azaindole derivatives is illustrated in Scheme F. This sequence of rections begins with protection of the 6-azaindole with an amine protecting group (PG2) to afford compound of general formula 20. The protection step is required to avoid competing side rections of the 2-aryltryptophol of formula 21 (where PG2 is H) in the later conversion of compound of formula 21 to compound of formula 22. The indole protection is followed by removal of the hydroxyl protecting group (PGl) from the side chain at the C-3 position of the 6-azaindole ring to afford compound of general formula 21. Finally, the hydroxyl group of 21 is converted to a primary amine of general formula 23 which is then further functionalized as shown below in the following schemes. The choice of an appropriate amine protecting group (PG2) for the 6-azaindole is determined primarily by which protect- ing group (PGl) is present on the hydroxyl group in the C-3 sidechain, and by consideration of the chemical stability of the amine protecting group (PGI) required in the remaining steps of the synthesis. When

the hydroxyl protecting group (PGl) is anO-benzyl ether as illustrated previously in Schemes C and D, the 6-azaindole may be protected as a carbamate derivative such as a tert-butylcarbamate (BOC). In this case, the BOC-protected 6-azaindole is stable under the hydrogenolysis conditions which are used to remove the O-benzyl ether and it may be conveniently removed at the end of the synthesis using acidic conditions.

If it is desired to synthesize compound of formula (I) wherein Ro is alkyl, substituted alkyl or the like, then it is possible to introduce that substituent at this point and the use of a protecting group and its subsequent removal is not required.

An alcohol of general formula 21 may be converted to a primary amine of general formula 23 using a variety of methods known in the literature of organic chemistry. The bottom of Scheme F illustrates a process where the alcohol 21 is first converted to an azide of general formula 22, followed by reduction to afford the amine derivative 23. The synthesis of an azide of general formula 22 from alcools like 21 is best accomplished by performing a Mitsunobu rection in the presence of an appropriate azide source such as diphenylphosphoryl azide or zinc azide pyridine complex. Scheme F illustrates the rection of alcohol 21 with triphenylphosphine, diethylazodicarboxylate, zinc azide pyridine complex and a proton source such as imidazole in an inert solvent like methylene chloride or tetrahydrofuran. The rection is usually conducted at room temperature for periods between 1-24 hours, typically overnight or about 15 hours, and affords the azide of general formula 22 in good yield.

Finally, an azide of formula 22 may then be reduced to an amine of formula 23 using one of several methods common in organic synthesis.

One preferred method is catalytic hydrogenation in a solvent like methanol or ethanol in the presence of a catalyst such as 10% palladium on carbon. Alternatively, azides like 22 may be reacted with triphenyl- phosphine to form an iminophosphorane which upon hydrolysis with water affords the amine of formula 23 and triphenylphophine oxide.

Rection Scheme G

The final stage of the synthesis of the novel 6-azaindole derivatives (I) involves elaboration of the sidechain at the C-3 position of the 6-azaindole core. One method for the completion of the synthesis is illustrated in Scheme G. As shown, the 2-aryltryptamine (23) may be condense with a carboxylic acid of type 24 using the coupling reagent 1- (3-dimethylamino-propyl)-3-ethylcarbodiimide hydrochloride (EDC), 1,3-dicyclohexyl-carbodiimide (DCC) or the like with or without 1- hydroxybenzotriazole (HOBt) and a tertiary amine base such as N- methylmorpholine (NMM), triethylamine or the like in an inert organic solvent such as methylene chloride, chloroform, dimethylformamide, or mixtures thereof at or near room temperature for a period of 3-24 hours to provide the corresponding amide derivative (25). Alternatively, 2- aryltryptamine 23 can be treated with an active ester or acid chloride of formula 26 in an inert organic solvent such as methylene chloride, chloroform, tetrahydrofuran, diethyl ether, or the like and a tertiary amine base such as triethylamine, diisopropylethylamine, pyridine or the like at a temperature of 0°-25°C for 30 minutes to 4 hours to give compound 25.

Rection Scheme H

As shown in rection Scheme H, the amide carbonyl of 25 can be reduced by treatment with borane, lithium aluminum hydride, or equivalent hydride sources in an inert organic solvent such as tetrahydrofuran, diethyl ether, 1,4-dioxane or the like at about 25°C to about 100°C, preferably about 65°C, for a period of 1-8 hours to give the corresponding amine 27.

Rection Scheme I Re R$ Ruz "s t< R2 (AR) R R7 > 1 z (CR9Rsa) NX jR (A) _R NjA R10 R10a, NXrA R10 R10a s N I \ R TFA, 31 sieves 3 3 22 ° R/QvR NaCNBH MeOH 28 R R v\RQ As shown in rection Scheme I, the 2-aryltryptamine 23 can be modifie by treatment with an aldehyde or ketone of type 28 in the presence of a weak acid such as trifluoroacetic acid (TFA), acetic acid or the like, with or without a dessicant such as 3A molecular sieves or magnesium sulfate, and a hydride source such as sodium borohydride or sodium cyanoborohydride, in an insert organic solvent such as methanol, ethanol, isopropanol, tetrahydrofuran, dichloromethane, chloroform, or mixtures thereof at a temperature of about 0° to about 25°C for a period of 1-12 hours to give the corresponding secondary or tertiary amine derivative 29.

Rection Scheme J

02N N02 R OR9R9a) nNH2 RoRoa S02CI > I R3 2, 4, 6-collidine, or R5 RQ OZN/NOZ Q I R$ O= Re I I R.CR9R9a) nNH 1. PPh3, DEAD, R.CR9R9aONyAR benzene I I R \R a N/ I I° R°a HO R 10 10 30 Rs N I \ R (A) > s N (\ R 29 Rs R4 2. n-propylamine As shown in rection Scheme J, the tryptamine 23 can be modifie using the Fukuyama modification of the Mitsunobu rection (Fukuyama, T.; Jow, C.-K.; Cheung, M. Tetrahedron Lett. 1995,36,6373- 74). The tryptamine 23 may be reacted with an arylsufonyl chloride such as 2-nitrobenzene-sulfonyl chloride, 4-nitrobenzenesulfonyl chloride or 2,4-dinitrobenzene-sulfonyl chloride and a hindered amine base such as 2,4,6-collidine, 2,6-lutidine or the like in an inert organic solvent such as methylene chloride to provide the corresponding sulfonamide 30. The sulfonamides can be further modifie by rection with an alcohol of type 31 in the presence of triphenylphosphine and an activating agent such as diethylazodicarboxylate (DEAD), diisopropylazodicaboxylate or the like in an inert organic solvent such as benzene, toluene, tetrahydrofuran or mixtures thereof to give the dialkylsulfonamide adduct. Removal of a dinitrobenzenesulfonyl group is accomplished by treatment with a nucleophilic amine such as n-propylamine or the like in an inert organic solvent such as methylene chloride to give secondary amines of type 32.

When a mono-nitrobenzenesulfonyl derivative is employed, the removal of the sulfonamide is accomplished with a more nucleophilic reagent such as thiophenol or mercaptoacetic acid in combination with lithium hydroxide in DMF.

Rection Scheme K R8 I (CRyIZ9a)OH OZN/NOZ 1. pPh, DEAD, 'I benzene RoRoa 0 \ 2. n-propylamine HN (Aj R 32 3. Remove PG2 20 R5 R4 (A)- R8 H Rj. OR9R9a)NyAR 1 Iooa N, Rs I R3 31 ru

Rection Scheme K illustrates a method that is complimentary to rection Scheme J for completing the synthesis of the novel compound of formula (I). Scheme K also employs the Fukuyama modification of the Mitsunobu rection similar to that illustrated in rection Scheme J. However in this instance, the alcohol partner employed is a 2-aryltryptophol of general formula 21 which has been decribed previously in rection Scheme F. The 2-aryltryptophol (21) is reacted with a substituted sulfonamide of general formula 33, triphenylphosphine and diethylazodicarboxylate in a suitable inert organic solvent such as benzene, tetrahydrofuran, 1,4-dioxane or the like.

The rection is generally conducted at room temperature for a period of 2 to 24 hours, typically overnight or for about 12-16 hours. The product is an N, N-disubstituted sulfonamide which is then separately subjected to rection with a base such as 7l-propylamine which removes the sulfonamide substituent and furnishes a secondary amine related to formula 32. The sulfonamides of formula 33 employed are readily obtained from a primary amine and either 2-nitrobenzenesulfonyl chloride, 4-nitrobenzenesulfonyl chloride or 2,4-dinitrobenzenesulfonyl chloride (as shown) in the presence of a hindered amine base such as

2,4,6-collidine, 2,6-lutidine or the like in an inert organic solvent such as methylene chloride. The final stage of the synthesis requires removal of the protecting group on the 6-azaindole nitrogen atom (PG2) which produces a compound of general formula 32 wherein Ro is a hydrogen atom. It will be recognized by individuals skilled in the art of organic synthesis that a preference for utilizing either the synthetic sequences outlined in rection Schemes J or K will be determined by the substituents selected to be present in the compound of formula (I).

The compound of the present invention are useful in the treatment of various sex-hormone related conditions in men and women. This utility is manifeste in their ability to act as antagonists of the neuropeptide hormone GnRH as demonstrated by activity in the following i71 vitro assays.

Rat pituitary GnRH receptor bindin assay: Crude plasma membranes prepared from rat pituitary tissues were incubated in a Tris. HCl buffer (50 mM, PH. 7.5) containing bovine serum albumin (. 1%), [I-125] D-t-Bu-Ser6-Pro9-ethyl amide-GnRH, and the desired concentration of a test compound. The assay mixtures were incubated at 4°C for 90-120 minutes followed by rapid filtration and repeated washings through a glass fiber filter. The radioactivity of membrane bound radioligands was determined in a gamma-counter.

From this data, the ICso of the radioligand binding to GnRH receptors in the presence of test compound was estimated.

Inhibition of LH release assay: Active compound from the GnRH receptor binding assay were further evaluated with an in vitro LH release assay to confirm their antagonist activity (blocking GnRH-induced LH release).

1. Sample Preparation The compound to be assayed were dissolve and diluted in DMSO. The final concentration of DMSO in the incubation medium was 0.5%.

2. Assai The Wistar male rats (150-200 grams) were obtained from Charles River Laboratories (Wilmington, MA). Rats were maintained at a constant temperature (25°C) on a 12-hr light, 12-hr dark cycle. Rat chow and water were available ad libitum. The animals were sacrifice by decapitation and pituitary glands were aseptically removed and placed in Hank's Balance Salt Solution (HBSS) in a 50-mL polypropylene centrifuge tube. The collection tube was centrifuged for 5 min at 250 x g, and HBSS was removed by aspiration. Pituitary glands were transferred to a disposable petri plate and minced with a scalpel. The minced tissue was then transferred to a 50-mL disposable centrifuge tube by suspending the tissue fragments in three successive 10-mL aliquots of HBSS contai- ing 0.2% collagenase and 0.2% hyaluronidase. The cell dispersion was carried out in a water bath at 37°C with gentle stirring for 30 min. At the end of the incubation, the cells were aspirated 20 to 30 times with a pipet and the undigested pituitary fragments were allowed to settle for 3 to 5 min. The suspende cells were removed by aspiration, and then subjected to a 1200 x g centrifugation for 5 min. The cells were then resuspended in Culture medium. The undigested pituitary fragments were treated with 30 mL aliquots of the digestion enzymes as above for a total of 3 digestions with the collagenase/hyaluronidase mixture. The resulting cell suspensions were pooled, counted and diluted to a concentration of 3 x 105 cells/ml, and 1.0 ml of this suspension was placed in each well of a 24-well tray (Costar, Cambridge, MA). Cells were maintained in a humidifie 5% C02-95% air atmosphere at 37°C for 3 to 4 days. The culture medium consiste of DMEM containing 0.37% NaHCO3,10% horse serum, 2.5% fetal bovine serum, 1% non-essential amino acids, 1% glutamine, and 0.1% gentamycin. On the day of an experiment, cells were washed three times 1 1/2 hrs prior to and two more times immediately before the start of the expriment with DMEM containing 0.37% NaHC03,10% horse serum, 2.5% fetal bovine serum, 1% non-essential amino acids (lOOX), 1% glutamine (100X), 1% Penicillin/Streptomycin (10,000 Units of Penicillin and 10,000 micrograms of Streptomycin per ml), and 25 mM HEPES, pH

7.4. LH release was initiated by adding 1 ml of fresh medium containing test compound in the presence of 2 nM GnRH to each well in duplicate.

Incubation was carried out at 37°C for 3 hr. After incubation, medium was removed and centrifuged at 2,000 x g for 15 min to remove any cellular material. The supernatant fluid was removed and assayed for LH content with a double antibody RIA procedure using materials obtained from Dr. A. F. Parlow (Harbor-UCLA Medical Center, Torrance, CA).

The compound ouf-formula I are useful in a number of areas affecte by GnRH. They may be useful in sex-hormone related conditions, sex-hormone dependent cancers, benign prostatic hypertrophy or myoma of the uterus. Sex-hormone dependent cancers which may benefit from the administration of the compound of this invention include prostatic cancer, uterine cancer, breast cancer and pituitary gonadotrophe adenomas. Other sex-hormone dependent conditions which may benefit from the administration of the compound of this invention include endometriosis, polycystic ovarian disease, uterine fibroids and precocious puberty. The compound may also be used in combination with an angiotensin-converting enzyme inhibitor such as Enalapril or Captopril, an angiotensin II-receptor antagonist such as Losartan or a renin inhibitor for the treatment of uterine fibroids.

The compound of the invention may also be useful for controlling pregnancy, as a contraceptive in both men and women, for in vitro fertilization, in the treatment of premenstrual syndrome, in the treatment of lupus erythematosis, in the treatment of hirsutism, in the treatment of irritable bowel syndrome and for the treatment of sleep disorders such as sleep apnea.

A further use of the compound of this invention is as an adjunct to growth hormone therapy in growth hormone deficient children. The compound may be administered with growth hormone or a compound which increases the endogenous production or release of growth hormone. Certain compound have been developed which stimulate the release of endogenous growth hormone. Peptides which are known to stimulate the release of endogenous growth hormone include growth hormone releasing hormone, the growth hormone

releasing peptides GHRP-6 and GHRP-1 (described in U. S. Patent No.

4,411,890, PCT Patent Pub. No. WO 89/07110, and PCT Patent Pub.

No. WO 89/07111) and GHRP-2 (described in PCT Patent Pub. No.

WO 93/04081), as well as hexarelin (J. Endocrinol Invest., 15 (Suppl 4), 45 (1992)). Other compound which stimulate the release of endogenous growth hormone are disclosed, for example, in the following: U. S. Patent No. 3,239,345; U. S. Patent No. 4,036,979; U. S. Patent No. 4,411,890; U. S.

Patent No. 5,206,235; U. S. Patent No. 5,283,241; U. S. Patent No.

5,284,841; U. S. Patent No. 5,310,737; U. S. Patent No. 5,317,017; U. S.

Patent No. 5,374,721; U. S. Patent No. 5,430,144; U. S. Patent No.

5,434,261; U. S. Patent No. 5,438,136; EPO Patent Pub. No. 0,144,230; EPO Patent Pub. No. 0,513,974; PCT Patent Pub. No. WO 94/07486; PCT Patent Pub. No. WO 94/08583; PCT Patent Pub. No. WO 94/11012; PCT Patent Pub. No. WO 94/13696; PCT Patent Pub. No. WO 94/19367; PCT Patent Pub. No. WO 95/03289; PCT Patent Pub. No. WO 95/03290; PCT Patent Pub. No. WO 95/09633; PCT Patent Pub. No. WO 95/11029; PCT Patent Pub. No. WO 95/12598; PCT Patent Pub. No. WO 95/13069; PCT Patent Pub. No. WO 95/14666; PCT Patent Pub. No. WO 95/16675; PCT Patent Pub. No. WO 95/16692; PCT Patent Pub. No. WO 95/17422; PCT Patent Pub. No. WO 95/17423; Science, 260,1640-1643 (June 11,1993); Ann. Rep. Med. Chem., 28,177-186 (1993); Bioorg. Med. Chem. Ltrs., 4 (22), 2709-2714 (1994); and Proc. Natl. Acad. Sci. USA 92,7001-7005 (July 1995).

Representative preferred growth hormone secretagoues employed in the present combination include the following: 1) N- [I (R)- [(1, 2-Dihydro-1-methanesulfonylspiro [3H-indole-3,4'- piperidin]-1'-yl)carbonyl]-2-(1H-indol-3-yl)ethyl]-2-amino-2 -methyl- propanamide; 2) N- [I (R)- [ (1, 2-Dlhydro-l-methanecarbonylspiro [3H-indole-3,4'- piperidin]-1'-yl)carbonyl]-2-(1H-indol-3-yl)ethyl]-2-amino-2 -methyl- propanamide;

3) N- [1 (R)- [ (1, 2-Dlhydro-l-benzenesulfonylspiro [3H-indole-3, 4'-piperidin]- 1'-yl)carbonyl]-2-(1H-indol-3-yl)ethyl]-2-amino-2-methyl-pro panamide; 4) N- [1 (R)- [ (3, 4-Dlhydro-spiro [2H-1-benzopyran-2, 4'-piperidin]-1'-yl) carbonyl]-2-(1H-indol-3-yl)ethyl]-2-amino-2-methylpropanamid e; 5) N- [1 (R)- [(2-Acetyl-1,2,3, 4-tetrahydrospiro [isoquinolin-4, 4'-piperidin]-1'- yl) carbonyl]-2- (indol-3-yl) ethyl]-2-amino-2-methyl-propanamide; 6) N- [1 (R)- [ (1, 2-Dlhydro-l-methanesulfonylspiro [3H-indole-3,4'- piperidin]-1'-yl)carbonyl]-2-(phenylmethyloxy)ethyl]-2-amino -2- methylpropanamide; 7) N- [1 (R)- [ (1, 2-Dlhydro-l-methanesulfonylspiro [3H-indole-3,4'- piperidin-1'-yl) carbonyl]-2- (phenylmethyloxy)ethyl]-2-amino-2- methylpropanamide methanesulfonate; 8) N- [1 (R)- [ (1, 2-Dlhydro-l-methanesulfonylspiro [3H-indole-3,4'- piperidin]-1'-yl)carbonyl]-2-(2',6'-difluorophenylmethyloxy) ethyl]-2-amino- 2-methylpropanamide; 9) N- [1 (R)- [ (1, 2-Dlhydro-l-methanesulfonyl-5-fluorospiro [3H-indole-3,4'- piperidin]-1'-yl)carbonyl]-2-(phenylmethyloxy)ethyl]-2-amino -2- methylpropanamide; 10) N- [1 (S)- [ (1, 2-Dlhydro-l-methanesulfonylspiro [3H-indole-3,4'- piperidin]-1'-yl)carbonyl]-2-(phenylmethylthio)ethyl]-2-amin o-2- methylpropanamide; 11) N-[1(R)-[(1,2-Dihydro-1-methanesulfonylspiro[3H-indole-3,4'- piperidin]-1'-yl)carbonyl]-3-phenylpropyl]-2-amino-2-methyl- propanamide;

12) N- [1 (R)- [(1, 2-Dihydro-1-methanesulfonylspiro [3H-indole-3,4'- piperidin]-1'-yl)carbonyl]-3-cyclohexylpropyl]-2-amino-2-met hyl- propanamide; 13) N- [1 (R)- [ (1, 2-Dlhydro-l-methanesulfonylspiro [3H-indole-3,4'- piperidin]-1'-yl) carbonyl]-4-phenylbutyl]-2-amino-2-methyl-propanamide; 14) N- [1 (R)- [(1,2-Dihydro-1-methanesulfonylspiro[3H-indole-3, 4'- piperidin]-1'-yl)carbonyl]-2-(5-fluoro-1H-indol-3-yl)ethyl]- 2-amino-2- methylprop anamide; 15) N- [1 (R)- [ (1, 2-Dihydro-1-methane sulfonyl-5-fluorospiro [3H-indole-3,4'- piperidin]-1'-yl)carbonyl]-2-(5-fluoro-1H-indol-3-yl)ethyl]- 2-amino-2- methylpropanamide; 16) N- [1 (R)- [ (1, 2-Dlhydro-l- (2-ethoxycarbonyl) methylsulfonylspiro- [3H- indole-3, 4'-piperidin]-1'-yl) carbonyl]-2- (1H-indol-3-yl) ethyl)-2-amino-2- methylpropanamide; 17) N- [1 (R)- [ (1, 2-Dlhydro-1,1-dioxospiro [3H-benzothiophene-3,4'- piperidin]-1'-yl)carbonyl]-2-(phenylmethyloxy)ethyl]-2-amino -2- methylpropanamide; and pharmaceutically acceptable salts thereof.

The compound of the invention may also be used in combination with bisphosphonates (bisphosphonic acids) and other agents, such as growth hormone secretagogues, for the treatment and the prevention of disturbances of calcium, phosphate and bone metabolism, in particular, for the prevention of bone loss during therapy with the GnRH antagonist, and in combination with estrogens, progesterones and or androgens for the prevention or treatment of bone loss or hypogonadal symptoms such as hot flashes during therapy with the GnRH antagonist.

Bisphosphonates (bisphosphonic acids) are known to inhibit bone resorption and are useful for the treatment of bone lithiasis as disclosed in U. S. Patent 4,621,077 to Rosini, et al.

The literature discloses a variety of bisphosphonic acids which are useful in the treatment and prevention of diseases involving bone resorption. Representative examples may be found in the following: U. S. Patent No. 3,251,907; U. S. Patent No. 3,422,137; U. S. Patent No.

3,584,125; U. S. Patent No. 3,940,436; U. S. Patent No. 3,944,599; U. S.

Patent No. 3,962,432; U. S. Patent No. 4,054,598; U. S. Patent No.

4,267,108; U. S. Patent No. 4,327,039; U. S. Patent No. 4,407,761; U. S.

Patent No. 4,578,376; U. S. Patent No. 4,621,077; U. S. Patent No.

4,624,947; U. S. Patent No. 4,746,654; U. S. Patent No. 4,761,406; U. S.

Patent No. 4,922,007; U. S. Patent No. 4,942,157; U. S. Patent No.

5,227,506; U. S. Patent No. 5,270,365; EPO Patent Pub. No. 0,252,504; and J. Org. Chem., 36,3843 (1971).

The preparation of bisphosphonic acids and halo- bisphosphonic acids is well known in the art. Representative examples may be found in the above mentioned references which disclose the compound as being useful for the treatment of disturbances of calcium or phosphate metabolism, in particular, as inhibitors of bone resorption.

Preferred bisphosphonates are selected from the group of the following compound: alendronic acid, etidrononic acid, clodronic acid, pamidronic acid, tiludronic acid, risedronic acid, 6-amino-1-hydroxy- hexylidene-bisphosphonic acid, and 1-hydroxy-3 (methylpentylamino)- propylidene-bisphosphonic acid; or any pharmaceutically acceptable salt thereof. A particularly preferred bisphosphonate is alendronic acid (alendronate), or a pharmaceutically acceptable salt thereof. An especially preferred bisphosphonate is alendronate sodium, including alendronate sodium trihydrate. Alendronate sodium has received regulatory approval for marketing in the United States under the trademark FOSAMAX.

Additionally, a compound of the present invention may be co-administered with a 5a-reductase 2 inhibitor, such as finasteride or epristeride; a 5α-reductase 1 inhibitor such as 4,7ß-dimethyl-4-aza-50C-

cholestan-3-one, 3-oxo-4-aza-4,7 (3-dimethyl-16 (3- (4-chlorophenoxy)-5a- androstane, and 3-oxo-4-aza-4,7ß-dimethyl-16ß-(phenoxy)-50C-androstane as disclosed in WO 93/23420 and WO 95/11254; dual inhibitors of 5a- reductase 1 and 5ce-reductase 2 such as 3-oxo-4-aza-17 (3- (2,5-trifluoro- ethylphenyl-carbamoyl)-5a-androstane as disclosed in WO 95/07927; antiandrogens such as flutamide, casodex and cyproterone acetate, and alpha-1 blockers such as prazosin, terazosin, doxazosin, tamsulosin, and alfuzosin.

Further, a compound of the present invention may be used in combination with growth hormone, growth hormone releasing hormone or growth hormone secretagogues, to delay puberty in growth hormone deficient children, which will allow them to continue to gain height before fusion of the epiphyses and cessation of growth at puberty. Further, a compound of the present invention may be used in combination or co- administered with a compound having luteinizing hormone releasing activity such as a peptide or natural hormone or analog thereof. Such peptide compound include leuprorelin, gonadorelin, buserelin, triptorelin, goserelin, nafarelin, histrelin, deslorelin, meterlin and recirelin.

For combination treatment with more than one active agent, where the active agents are in separate dosage formulations, the active agents may be administered separately or in conjunction. In addition the administration of one element may be prior to, concurrent to, or subsequent to the administration of the other agent.

The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tables, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, mulsions, hard or soft capsules, or syrups or elixirs.

Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatale preparations. Tablets contain

the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tables.

These excipients may-be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid ; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the technique described in the U. S. Patent 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.

Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.

Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl-cellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcools, for example heptadecaethylene-oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-

propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.

Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcool. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatale oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.

The pharmaceutical compositions of the invention may also be in the form of an oil-in-water mulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring phosphatides, for example soy beans, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The mulsions may also contain sweetening and flavouring agents.

Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.

The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may

be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono-or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

Compound of Formula I may also be administered in the form of a suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non- irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.

For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compound of Formula I are employed.

(For purposes of this application, topical application shall include mouth washes and gargles.) The compound for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in the art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen. Compound of the present invention may also be delivered as a suppository employing bases such as cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol.

The dosage regimen utilizing the compound of the present invention is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound thereof employed. A physician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to prevent, conter, arrest or reverse the progress of the condition. Optimal precision in achieving concentration of drug within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the drug's availability to target sites.

This involves a consideration of the distribution, equilibrium, and elimination of a drug. Preferably, doses of the compound of structural formula I useful in the method of the present invention range from 0.01 to 1000 mg per adult human per day. Most preferably, dosages range from 0.1 to 500 mg/day. For oral administration, the compositions are preferably provided in the form of tablets containing 0.01 to 1000 milligrams of the active ingredient, particularly 0.01, 0.05,0.1,0.5,1.0,2.5,5.0,10.0,15.0,25.0,50.0,100 and 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. An effective amount of the drug is ordinarily supplie at a dosage level of from about 0.0002 mg/kg to about 50 mg/kg of body weight per day. The range is more particularly from about 0.001 mg/kg to 1 mg/kg of body weight per daN.

Advantageously, the active agent of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in dividend doses of two, three or four times daily.

The amount of active ingredient that may be combine with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.

It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the

age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

The following examples illustrate the preparation of some of the compound of the invention and are not to be construed as limiting the invention disclosed herein.

EXAMPLE 1 (S)-1-(2-Azabicyclo[2. 2.2] oct-2-yl)-2- {2- (3,5-dimethylphenvl)-3- <BR> <BR> jl-methvl-2-(2-pvridin-4-vlethylamino)ethy'-1H-pryroloj2,3-c ]pryidin<BR> <BR> <BR> <BR> -5-vl-2-methvlpropan-1-one Step IA: (S)-1-(2-Azabicyclo [2.2.2] oct-2-yl)-2-f 2- (3, 5-dimethylphenylj- 3- [2- [N- (2,4-dinitrobenzenesulfonyl), N- (2-pyridin-4-ylethyl)- amino]-1-methylethyl]-IH- (tert-butoxycarbonyl)pyrrolo- [2,3-c]pyridin-5-yl}-2-methylpropan-1-one DEAD (59.8 µL, 0.380 mmol) was added dropwise via syringe to a stirred solution of (S)-l- (2-azabicyclo [2.2.2] oct-2-yl)-2-{2-(3, 5- dimethyl-phenyl)-3- [2- (2, 4-dinitrobenzenesulfonylamino)-l-methylethyl]- 1H- (tert-butoxy-carbonyl) pyrrolo [2,3-c] pyridin-5-yl}-2-methylprop an-1-one (150 mg, 0.190 mmol), 4- (2-hydroxyethyl)-pyridine (46.8 mg, 0.380 mmol) and PPh3 (99.7 mg, 0.380 mmol) in benzene (2 mL) at room temperature.

After approximately lh, the rection mixture was concentrated ira vacuo and the residue was partially purifie by flash chromatography on silica gel (80% ethyl acetate/hexanes as eluent) to give a mixture of the title compound, 1,2-dicarbethoxyhydrazine and triphenylphosphine oxide.

Step 1B: (S)-1- (2-Azabicyclo [2.2.2] oct-2-yl)-2- {2- (3,5-dimethylphenyl)- 3-1-methyl-2-(2-pyridin-4-ylethylamino) ethyl]-lH-(tert- butoxycarbonyl) pyrrolo [2,3-c] pyridin-5-yl}-2-methylprop an-1- one n-Propylamine (391 L, 4.'75 mmol.) was added to a stirred solution of crude (S)-1-(2-azabicyclo [2.2.2] oct-2-yl)-2-{2-(3, 5- dimethylphenyl)-3- [2- [N- (2,4-dinitrobenzenesulfonyl), N- (2-pyridin-4- ylethyl) amino]-I-methylethyl]-IH- (tert-butoxycarbonyl) pyrrolo [2,3- c] pyridin-5-yl}-2-methylpropan-1-one (0.190 mmol.) in CH2Cl2 (2 mL) at room temperature. After approximately 15 min., the volatiles were evaporated in vacuo and the residue was purifie by preparative thin layer chromatography on silica gel (double elution using 100% ethyl acetate as eluent) to give the title compound as a foam (94.6 mg, 75% overall yield for two steps).

Step 1C: (S)-1-(2-Azabicyclo [2.2.2] oct-2-yl)-2-{2-(3, 5-dimethylphenyl)- 3- [l-methyl-2- (2-pyridin-4-ylethylamino) ethyl]-IH-pyrrolo- [2,3-c]-pyridin-5-yl}-2-methylpropan-1-one A solution of (S)-1-(2-azabicyclo [2.2.2] oct-2-yl)-2-{2-(3, 5- dimethylphenyl)-3- [I-methyl-2- (2-pyridin-4-ylethylamino) ethyl]-lH- (tert-butoxycarbonyl)-pyrrolo [2,3-c] pyridin-5-yl}-2-methylpropan-1-one (65.0 mg, 97.9 µmol) in trifluoroacetic acid/CH2Cl2 (1: 4; 1 mL) was aged at room temperature for approximately 9h. The resulting mixture was concentrated i7l vacuo and the residue partitioned between saturated aqueous NaHCOs and CH2Cl2. The organic phase was separated and the aqueous phase re-extracted with CH2Cl2 (x3). The combine organic extract was washed with brine, dried (MgS04) and concentrated i71 vacuo.

The residue was purifie by flash chromatography on silica gel (gradient elution; 2-4% methanol/1% NH4OH/CH2Cl2 as eluent) to give the title compound as a foam (53.4 mg, 97%).

MS (ESI) 771le = 564.6 (M+H+).

EXAMPLE 2 (S)-1-(2-Azabicyclo[2.2.2]oct-2-yl)-2-[3-{2-[2-(1H)-benzotri azol- 5-yl)-ethylamino]-1-methylethyl}-2-(3,5-dimethylphenyl)- 1H-pyrrolo[2,3-c]pyridin-5-yl]-2-methylpropan-1-one Step 2A: (S)-1-(2-Azabicyclo [2.2.2] oct-2-yl)-2-{2-(3, 5-dimethylphenyl)- 3-2- [N-(2, 4-dinitrobenzenesulfonyl), N- (2- [I- (2-trimethylsilyl- ethoxymethyl)-1H-benzotriazol-5-yl] ethyl) amino]-1-methyl- ethyl]-1H-(tert-butoxycarbonyl)(tert-butoxycarbonyl) pyrrolo [2,3-c] pyridin-5-yl}-2- methylpropan-1-one DEAD (64.3 I1L, 0.409 mmol) was added dropwise via syringe to a stirred solution of (S)-1-(2-Azabicyclo [2.2.2] oct-2-yl)-2- {2-(3, 5- dimethylphenyl)-3- [2- (2, 4-dinitrobenzenesulfonylamino)-l-methylethyl]- 1H-(tert-butoxy-carbonyl)pyrrolo[2,3-c]pyridin-5-yl}-2-methy lpropan- 1-one (170 mg, 0.215 mmol), 2- [I- (2-trimethylsilylethoxymethyl)-IH- benzotriazol-5-yl] ethanol (120 mg, 0.409 mmol) and PPh3 (107 mg, 0.409 mmol) in benzene (2 mL) at room temperature. After approximately 1.5h, the rection mixture was concentrated in vacuo and the residue was partially purifie by flash chromatography on silica gel (40-60% ethyl acetate/hexanes as eluent) to give a mixture of the title compound, 1,2- dicarbethoxyhydrazine, triphenylphosphine oxide and the recovered benzotriazole component.

Step 2B: (S)-1- (2-Azabicyclo [2.2.2] oct-2-yl)-2- {2- (3,5-dimethylphenyl)- 3-2- [2- [I- (2-trimethylsilylethoxymethyl)-IH-benzotriazol-5- yl]-ethylamino]-1-methylethyl}-1H-(tert-butoxycarbonyl)

Pyrrolo- [2,3-c]p,yridin-5--2-methvlpropan-1-one n-Propylamine (442 L, 5.38 mmol.) was added to a stirred solution of crude (S)-1-(2-azabicyclo [2.2.2) oct-2-yl)-2- {2- (3,5- dimethylphenyl)-3- [2- [N- (2,4-dinitrobenzenesulfonyl), N- (2- [l- (2- trimethylsilylethoxy-methyl)-1H-benzo-triazol-5-yl] ethyl) amino]-1- methylethyl]-1H-(tert-butoxycarbonyl)pyrrolo-[2,3-c]pyridin- 5-yl}-2- methyl-propan-1-one (0.215 mmol.) in CH2Cl2 (2 mL) at room temperature. After approximately 10 min., the volatiles were evaporated in vacuo and the residue was partially purifie by preparative thin layer chromatography on silica gel (double elution using 100% ethyl acetate as eluent) to give the title compound as a foam.

Step 2C: (S)-1- (2-Azabicyclo [2.2.2oct-2-yl)-2- [3-2- [2- (lH-benzotriazol- 5-yl) ethylamino]-l-methylethyll-2- (3, 5-dimethylphenyl)-1 H-pyrrolo [2,3-c] pyridin-5-yl]-2-methylpropan-1-one trifluoroacetic acid salt A vigorously stirred suspension of crude (S)-I- (2- azabicyclo [2.2.2] oct-2-yl)-2-{2-(3,5-dimethylphenyl)-3-2- [2- [l- (2- trimethylsilylethoxymethyl)-1H-benzo-triazol-5-yl]-ethylamin o]-1- methylethyl}-1H- (tert-butoxycarbonyl)-pyrrolo [2,3-c] pyridin-5-yll-2- methyl-propan-1-one (0.215 mmol.) and 2N HCI/EtOH (1: 1; 1 mL) was heated at 75°C for approximately 3h. After cooling to ambient temperature, the rection mixture was basified to pH=9 with 2N NaOH, and then extracted with dichloromethane (x3). The combine organic extract was washed with brine, dried (MgSO4) and concentrated in uacico.

The residue was purified by reverse phase HPLC (Waters Delta Pak 15µ, C18, 100Å19x300 mmcolumn; 25% 0.1%- trifluoroacetic acid as eluent) to give the title compound as a solid (65 mg, 37% overall yield for the three steps).

MS (ESI) mle = 604.7 (M+H+).

EXAMPLE 3 1-(2-Azabicyclo[2,2,2]oct-2-yl)-2-(2-(3,5-dimethylphenyul)-3 -{1- methyl-2-[2-(2-methyl-1-oxopyridin-4-yl)ethylamino]ethyl}-1H - pyrrolo[2,3-c]pyridin-5-yl)-2-methylpropan-1-one Step 3A: (S)-1-(2-Azabicyclo [2.2.2) oct-2-yl)-2- {2- (3,5-dimethylphenyl)- 3- [2- (N- (2,4-dinitrobenzenesulfonyl), N- (2- (2-methyl-1-oxo- pyridin-4-yl) ethyl) amino]-1-methylethyl]-IH- (tert-butoxy- carbonvlpvrroloj2,3-c]pvridin-5-yl}-2-methylpropan-1-one DEAD (80.0 pL, 0.508 mmol) was added dropwise via syringe to a stirred solution of (S)-1-(2-azabicyclo [2.2.2] oct-2-yl)-2-f2- (3,5- dimethylphenyl)-3- [2- (2, 4-dinitrobenzenesulfonylamino)-1-methylethyl]- 1H- (tert-butoxycarbonyl)-pyrrolo [2,3-c] pyridin-5-yl}-2-methylpropan-1-one (200 mg, 0.254 mmol), 4- (2-hydroxyethyl)-2-methylpyridin-1-oxide (77.8 mg, 0.508 mmol) and PPh3 (133 mg, 0.508 mmol) in benzene (5 mL) at room temperature. After approximately 1.5h, the rection mixture was concentrated ion vacuo and the residue was partially purifie by flash chromatography on silica gel (100% CH2Cl2 then 3% MeOH/CH2Cl2 as eluent) to give the title compound as a foam.

Step 3B: (S)-1-(2-Azabicyclo [2.2.2] oct-2-yl)-2-{2-(3, 5-dimethylphenyl)- 3-(2- (2-methyl-1-oxopyridin-4-ylethylamino)-1-methylethyl]- 1H- (tert-butoxycarbonyl)-pyrrolo [2,3-c] pyridin-5-yl}-2- methvlpropan-1-one 7l-Propylamine (520 µL, 6.35 mmol.) was added to a

stirred solution of crude (S)-1-(2-azabicyclo [2.2.2] oct-2-yl)-2-{2-(3, 5- dimethylphenyl)-3- [2- [N- (2,4-dinitrobenzenesulfonyl), N- (2- (2-methyl-1- oxopyridin-4-yl)ethyl)-amino]-1-methylethyl]-lH-(tert-butoxy carbonyl) pyrrolo [2,3-c] pyridin-5-yl}-2-methylpropan-1-one (0.254 mmol.) in CH2C12 (2.5 mL) at room temperature. After approximately 2h, the volatiles were evaporated i71 vacuo and the residue was purifie by flash chromatography on silica gel (100% CH2Cl2 then 3-5% MeOH/1% NH40H/ CH2Cl2 as eluent) to give the title compound as a foam (141 mg, 80% overall yield for two steps).

Step 3C: 1- (2-Azabicyclo [2.2.2] oct-2-yl)-2- (2- (3,5-dimethylphenyl)- 3-{1-methyl-2-[2-(2-methyl-1-oxopyridin-4-yl)ethylamino] ethyl}-lH-pyrrolo [2,3-c] pyridin-5-yl)-2-methylpropan- 1-one trifluoroacetic acid salt A solution of (S)-1-(2-azabicyclo [2.2.2] oct-2-yl)-2-{2-(3, 5- dimethylphenyl)-3-[2-(2-methyl-1-oxopyridin-4-yl-ethylamino) -1- methylethyl)-1H- (tert-butoxy-carbonyl)-pyrrolo [2,3-c] pyri din-5-yll-2- methylpropan-1-one (140 mg, 0.202 mmol) in trifluoroacetic acid/ CH2Cl2 (1: 1; 2 mL) was aged at room temperature for approximately 2h. The resulting mixture was concentrated in vacuo and the residue purifie by reverse phase HPLC (Waters Delta Pak 15p, C18,100A 19x300 mm column; gradient elution 27-32% acetonitrile/water-0.1% trifluoroacetic acid) to give the title compound as a solid (128 mg, 77%).

MS (ESI) m/e= 594.4 (M+H+).

EXAMPLE 4 Following procedures similar to those described in Examples 1,2 and 3 and in Schemes A to K, the following compound are prepared:

PREPARATION OF SYNTHETIC INTERMEDIATES (S)- (4-Benzvloxy-3-methylbut-l-vnvl)triethvlsilane Step A: Methyl (S)-3-benzyloxy-2-methylpropanoate An oven dried 1 L single-necked round bottom flask was equipped with a magnetic stir bar and then charged sequentially with 15.948 g (0.135 mol) of (R)- (-)-methyl-3-hydroxy-2-methylpropanoate, carbon tetrachloride (150 mL), cyclohexane (300 mL), and 35.796 g (0.142 mol) of benzyl 2,2,2-trichloroacetimidate. Trifluoromethanesulfonic acid (0.8 mL; 9.0 mmol) was added to the solution and the resulting mixture was stirred for 16 h at room temperature under an N2 atmosphere. The rection mixture was then filtered and the filtrate concentrated tit vacuo.

The residue was redissolved in 150 mL EtOAc and extracted with saturated aqueous NaHCO3 (1x100 mL). The organic layer was washed with saturated NaCl, dried (MgSO i), filtered and evaporated. The residual oil was purifie on a silica gel flash chromatography column eluted with 10% EtOAc-hexane. The purifie fractions were combine and evaporated in vacuo to afford 20.787g of the title compound as an oil.

MS (CI): in le = 209 (M+1).

Step B: (S)-3-Benzyloxy-2-methylpropan-1-ol An oven dried three-necked 2 L round bottom flask was equipped with a mechanical stirrer, a reflux condenser and a 500 mL constant pressure addition funnel. The flask was charged with a solution

of 62.252 g (0.299 mol) of methyl (S)-3-benzyloxy-2-methylpropanoate in 600 mL of anhydrous THF, and a 1.0 M solution of lithium aluminum hydride (300 mL; 0.3 mol) was transferred into the dropping funnel via a canula. Stirring was started and the lithium aluminum hydride solution was added over 45 minutes to the rection under an N2 atmosphere while the temperature of the rection mixture was maintained between 25-30°C using an external ice-water bath. After the addition was complete, the rection was stirred an additional 6 h at room temperature at which point TLC analysis (20% EtOAc-hexane) indicated complete rection. The rection mixture was then cooled with an external ice-water bath and quenched by serial addition of 11.4 mL water, 11.4 mL of 15% aqueous NaOH, and 34.2 mL water. The rection mixture was then filtered, the solids were washed with EtOAc, the filtrate and washings were combine and evaporated iv uacuo. The residue was redissolved in EtOAc, washed with 10% aqueous NaHS04, saturated NaCl, dried (MgS04), filtered and evaporated. The residue was purifie by Kugelrohr distillation to afford 47.67 g of the title compound as an oil.

MS (CI): 7nle = 181 (M+1).

Step C: (S)-3-Benzyloxy-2-methylpropanal An oven dried three-necked 2 L round bottom flask was equipped with a mechanical stirrer, a thermometer, an N2 inlet, and a septum. The flask was charged with 24.050 g (0.189 mol) of oxalyl chloride and 425 mL CH2Cl2. The rection mixture was stirred under an N2 atmosphere and cooled to-78°C with an external dry ice-acetone bath.

A solution of methyl sulfoxide (29.607 g; 0.379 mol) in 85 mL CH2Cl2 was then added over 5 min to the rection mixture via canula. After the adition, the rection was stirred an additional 5 min and then a solution of 31.048 g (0.172 mol) of (S)-3-benzyloxy-2-methylpropan-1-ol in 170 mL CH2Cl2 was added via canula. When the second addition was completed the rection mixture was stirred for 15 min at-78'C then 111.32 g (0.861 mol) of N, N-diisopropylethylamine was added via syringe. The rection mixture was stirred an addition 15 min at-78°C, the cooling bath was removed and the rection was allowed to warm. When the internal

temperature had reached-15°C, 350 mL of a 10% aqueous NaHSO4 solution was slowly added and the mixture was transferred to a separatory funnel. The organic layer was separated, washed with aqueous NaHSO4 (2x250 mL), saturated NaCl, dried (MgS04), filtered and evaporated. The residue was used immediately in the next step without further purification.

Step D: -4-Benzvloxv-1,1-dibromo-3-methylbutene An oven dried three-necked 2 L round bottom flask was equipped with a mechanical stirrer, a thermometer, an N2 inlet, and a septum. The flask was charged with 180.71 g (0.689 mol) of triphenyl- phosphine and 925 mL of CH2Cl2. The rection mixture was stirred under an N2 atmosphere and cooled to 0-5°C with an external ice-water bath. The septum was then removed and 114.25 g (0.344 mol) of carbon tetrabromide was added in portions through the open neck of the flask at a rate that maintained the temperature of the rection mixture below 20°C. After the addition was complete the rection was stirred for 1 h and then a solution of the (S)-3-benzyloxy-2-methylpropanal from the previous step dissolve in 150 mL of CH2Cl2 was added via cannula over a 5 min period. The rection mixture was stirred under N2 for an additional 1 h and allowed to warm to room temperature. A separate 10 L three-necked round bottom flask was equipped with a mechanical stirrer and charged with 4 L of hexane. The stirrer was started and the crude rection mixture was introduced as a slow stream which resulted in formation of a granular precipitate. After the transfer was complete the rection mixture was filtered and the solids were carefully washed with hexane.

The filtrate was evaporated i77 vacuo and additional solids were deposited.

The residue was resuspended in hexane, filtered and the filtrate reevaporated. The resulting oil was purifie by Kugelrohr distillation to afford 46.54 g of the title compound as an oil.

Step E: (S)- (4-benzyloxy-3-methylbut-l-vnyl) triethylsilane An oven dried 100 mL single-necked round bottom flask was equipped with a magnetic stir bar and a septum then charged with 5.171

g (15.5 mmol) of (S ?-4-benzyloxy-1, 1-dibromo-3-methylbutene and 20 mL of anhydrous THF. The rection mixture was stirred at-78°C under an N2 atmosphere and 12.4 mL of a 2.5 M solution of rz-butyllithium (31.0 mmol) was added dropwise via syringe over 15 min. The rection mixture was stirred at-78°C for an additional 1 h, then quenched with 10% aqueous NaHS04 and extracted into EtOAc. The organic layer was washed with water (3x25 mL), sturated NaCl, then dried (MgSO4), filtered, and evaporated. The residue was purifie by Kugelrohr distillation to afford 3.999 g of the title compound as an oil.

(S)-1- (2-Azabicycloj2.2. 2]oct-2-yl)-2-{2-(3,5-dimethylphenyl)-3-[2-(2, 4- dinitrobenzenesulfonvlamino)-1-methvlethyl]-1H- (tert-butoxy- carbonyl)pyrrolo[2,3-c]pyrdin-5-yl}-2-methylpropan-1-one Step AA: tert-Butyl methvl 2- (5-nitropvridin-2-vl) malonate Tert-Butylmethylmalonate (50.1 mL, 0.296 mol.) was added dropwise, via pressure equalizing addition funnel, to a vigorously stirred solution of 2-chloropyridine (23.4 g, 0.148 mol.) and sodium hydride (11.8 g of a 60% dispersion in mineral oil, 0.296 mol.) in N, N- dimethylformamide at room temperature. An exothermic rection was observe! After the initial exotherm had subside, the rection mixture was maintained at 50°C for approximately 6h. Upon cooling to ambient temperature, the rection mixture was poured into water and extracted with ethyl acetate (x3). The combine organic extract was washed with water, brine, dried (MgSO4) and concentrated i71 vacuo. The residual

yellow oil was sufficiently pure to be used without further purification in the subsequent rection.

Step BB: (5-nitropyridin-2-yl)acetate Trifluoroacetic acid (34.2 mL, 0.444 mol.) was added, via syringe, to a stirred solution of crude tert-butyl methyl 2- (5-nitropyridin- 2-yl) malonate (0.148 mol.) in dichloromethane (500 mL) at ambient temperature. After approximately 2h, the rection mixture was poured cautiously onto cold saturated aqueous NaHCO3 and extracted with ethyl acetate (x3). The combine organic extract was washed with brine, dried (MgS04) and concentrated in vacuo. The residue was purifie by flash chromatography on silica gel (gradient elution; 25-40% ethyl acetate/ hexanes as eluent) to give the title compound as an orange oil (20.0 g, 69%).

Step CC: Methyl 2-methyl-2-(5-nitropyridin-2-yl)propionate A solution of methyl (5-nitropyridin-2-yl) acetate (20.0 g, 0.102 mol.) in N,N-dimethylformamide (50 mL) was added dropwise, via pressure equalizing addition funnel, to a stirred suspension of sodium hydride (12.2 g of a 60% dispersion in mineral oil, 0.306 mol.) in N, N- dimethylformamide (150 mL) at-20°C. After completion of addition, the rection mixture was warmed to 0°C and aged for approximately lh.

Cafter re-cooling to-20°C, methyl iodide (22.2 mL, 0.357 mol.) was added, via pressure equalizing addition funnel, so as to maintain the internal temperature between-15°C and-20°C. The resulting mixture was warmed to 0°C and aged for approximately 12h. The rection mixture was quenched with saturated aqueous NH4Cl, poured into water and extracted with ethyl acetate (x3). The combine organic extract was washed with brine, dried (MgS04) and concentrated in Uacuo. The residue was purifie by flash chromatography on silica gel (gradient elution; 10- 20% ethyl acetate/hexanes as eluent) to give the title compound as a pale yellow oil (17.5 g, 76%).

Step DD: Methyl 2-(5-aminopyridin-2-vl)-2-methylpropionate A mixture of methyl 2-methyl-2- (5-nitropyridin-2-yl) propionate (17.5 g, 78.0 mmol.) and and Pd/C (Pd-10%; 600 mg) in methanol (150 mL) was hydrogenated at 50 psi for 0.75h. An exothermic rection was observe! The resulting mixture was filtered through Celite'R washing copiously with methanol and the filtrate evaporated in vacuo.

The residual oil was sufficiently pure to be used without further purification in the subsequent rection.

Step EE: Methyl 2- [5- (2, 2-dimethylproplonylamino) pyridin- 2-vll-2-methylpropionate Trimethylacetyl chloride (11.5 mL, 93.6 mmol.) was added dropwise, via syringe, to a stirred solution of crude methyl 2- (5- aminopyridin-2-yl)-2-methylpropionate (78.0 mmol.) and triethylamine (13.0 mL, 93.6 mmol.) in a mixture of diethyl ether/THF (1: 1; 600 mL) at 0°C. After approximately 0.5h, the rection mixture was warmed to room temperature, poured into water and extracted with ethyl acetate (x3). The combine organic extract was washed with water, brine, dried (MgSO4) and concentrated 17L vacuo. The residual oil was sufficiently pure to be used without further purification in the subsequent rection.

Step FF: 2- [5- (2, 2-Dimethylproplonylamino) pyridin- 2-yl]-2-methyl-propionicacid A vigorously stirred suspension of crude methyl 2- [5- (2,2- dimethylpropionylamino) pyridin-2-yl)-2-methylpropionate (78.0 mmol.) and 2.5N NaOH (65.5 mL, 0.164 mol) in methanol (150 mL) was heated at 50°C for approximately 12h. After cooling to ambient temperature, the volatiles were evaporated in vacuo, and the residue diluted with dichloromethane. The resulting solution was acidifie to pH=5 with 2N HCl and extracted with dichloromethane (x3). The combine organic extract was washed with brine, dried (MgS04) and concentrated in vacuo.

The residual solid was sufficiently pure to be used without further purification in the subsequent rection.

Step GG: N-{6-[2-(2-Azabicyclo [2.2.2] oct-2-yl)-1, 1-dimethyl-2-oxoethyl]- pyridin-3-ylT-2 2-dimethylpropionamide PyBOP (42.6 g, 81.9 mmol) was added to a stirred mixture of crude 2- [5- (2, 2-dimethylpropionylamino)pyridin-2-yl]-2-methyl-propionic acid (78.0 mmol), isoquinuclidine HCl (12.7 g, 85.8 mmol) and triethylamine (23.9 mL, 172 mmol) in dichloromethane (150 mL) at room temperature. After approximately 12h, the rection mixture was poured into water/brine (1: 1) and extracted with dichloromethane (x3). The combine organic extract was washed with brine, dried (MgS04) and concentrated in vacuo. The residue was purifie by recrystallization from ethyl acetate/hexanes to give the title compound as colorless needles (25.1 g, 90% overall from the product of step CC).

Step HH: N-f6- [2- (2-Azabicyclo [2.2.2] oct-2-yl)-1,1-dimethyl-2-oxoethyl]- 4-iodopyridin-3-yl}-2, 2-dimethylpropionamide A solution of tert-butyllithium (20.6 mL of a 1.7M solution in hexanes, 35.0 mmol) was added dropwise, via syringe, to a stirred solution of N- {6- [2- (2-azabicyclo [2.2. 2]oct-2-yl)-1, 1-dimethyl-2-oxoethyl] pyridin-3- yl}-2, 2-dimethylpropionamide and N, N,N',N'-tetramethylethylenediamine (5.28 mL, 35.0 mmol.) in THF (50 mL) at-78°C. The resulting mixture was warmed to-45°C and aged for approximately 6h. After re-cooling to -78°C, a solution of iodine (8.88 g, 35.0 mmol.) in THF (20 mL) was added, via syringe, so as to maintain the interna temperature <60'C. After completion of addition, the rection mixture was allowed to warm to ambient temperature over approximately 6h and then quenched with saturated aqueous NH4Cl. The resulting mixture was poured into 1M Na2S203 and extracted with ethyl acetate (x3). The combine organic extract was washed with brine, dried (MgS04) and concentrated in vacuo.

The residue was purifie by flash chromatography on silica gel (gradient elution; 60-80% ethyl acetate/hexanes as eluent) to give in order of elution: the title compound as a pale yellow foam (4.67 g, 69%) followed by recovered starting material (1.21 g, 24%).

Step II: 2-(5-Amino-4-iodopyridin-2-yl)-1-(2-azabicyclo [2.2.2] oct-2-yl)-2-methylpropan-1-one A vigorously stirred mixture of N-{6-[2-(2-azabicyclo [2.2.2]oct-2-yl)-1,1-dimethyl-2-oxoethyl]-4-iodopyridin-3-yl }-2,2- dimethylpropionamide (4.66 g, 9.64 mmol.) in 24% H2SO4 (48 mL) was heated at 100°C for approximately 3.5h. After cooling to room temperature, the rection mixture was basified to pH=10 with 2.5N NaOH and then extracted with ethyl acetate (x3). The combine organic extract was washed with brine, dried (MgS04) and concentrated i71 vacuo. The residue was purifie by recrystallization from dichloromethane/diethyl ether to give the title compound as colorless prisms (3.02 g, 78%).

Step JJ: (S)-1-(2-Azabicyclo [2.2.2] oct-2-yl)-2- [3- (2-benzyloxy-l- methyl-ethyl)-2-triethylsilyl-lH-pyrrolo [2,3-c] pyridin- 5-vll-2-methvlpropan-1-one A vigorously stirred suspension of 2-(5-amino-4-iodopyridin- 2-yl)-1- (2-azabicyclo [2.2.2] oct-2-yl)-2-methylpropan-1-one (3.00 g, 7.51 mmol), (S)-(4-benzyloxy-3-methylbut-1-ynyl) triethylsilane (3.25 g, 11.3 mmol), Pd (dppf)Cl2#CH2Cl2 (0.307 g, 0.376 mmol), LiCl (0.318 g, 7.51 mmol) and Na2CO3 (1-99 9,18.8 mmol) in N, N-dimethylformamide (60 mL) was degassed via three vacuum/nitrogen ingress cycles, and the resulting mixture heated at 90°C for approximately 12h. After cooling to ambient temperature, the rection mixture was diluted with ethyl acetate and filtered through celiez washing copiously with ethyl acetate. The filtrate was poured into water/brine (1: 1) and the organic phase separated.

The aqueous phase was re-extracted with ethyl acetate (x2), the combine organic extract washed with brine, dried (MgSO4) and concentrated 1'71 uacuo. The residue was purifie by flash chromatography on silica gel (gradient elution; 70-80% ethyl acetate/hexanes as eluent) to give the title compound as a yellow foam (2.59 g, 62%).

Step KK: (S)-1-(2-Azabicyclo[2,2,2]oct-2-yl)-2-[3-(2-benzyloxy-1- methyl-ethyl)-2-iodo-lH-pyrrolo [2,3-c] pyridin-5-yl]- 2-methylpropan-1-one IPy2BF4 (2.51 g, 6.75 mmol.) was added in one portion to a stirred solution of (S)-1- (2-azabicyclo [2.2.2] oct-2-yl)-2- [3- (2-benzyloxy- 1-methyl-ethyl)-2-triethylsilyl-1H-pyrrolo [2,3-c] pyridin-5-yl]-2- methylpropan-1-one (2.52 g, 4.50 mmol.) in dichloromethane (45 mL) at room temperature. Trifluoromethanesulfonic acid (1.19 mL, 13.5 mmol.) was then added over approximately 3min, via syringe, and the resulting mixture stirred at ambient temperature for 1.5h. The rection mixture was poured into cold saturated aqueous NaHCO3/1M Na2S203 (1: 1) and extracted with ethyl acetate (x3). The combine organic extract was washed with water, brine, dried (MgSO4) and concentrated t7L vacuo.

The residue was purifie by flash chromatography on silica gel (gradient elution; 70-85% ethyl acetate/hexanes as eluent) to give the title compound as a pale yellow foam (2.50 g, 97%).

Step LL: (S)-1-(2-Azabicyclo [2.2.2] oct-2-yl)-2- [3- (2-benzyloxy-l-methyl- ethyl)-2-(3,5-dimethylphenyl)-1H-pyrrolo[2,3-c]pyridin-5-yl] - 2-methylpropan-1-one A vigorously stirred suspension of (, S-1- (2-azabicyclo [2.2.2] oet-2-yl)-2- [3- (2-benzyloxy-l-methyl-ethyl)-2-lodo-IH-pyrrolo [2,3-c] pyridin-5-yl-2-methylpropan-1-one (2.50 g ? 4.37 mmol), 2,5- dimethylphenylboronic acid (1.31 g, 8.74 mmol) and Pd (dppf) C12-CH2CI2 (0.178 g, 0.219 mmol) in toluene/MeOH (5: 2; 42 mL) was degassed via three vacuum/nitrogen ingress cycles, and the resulting mixture heated to 80°C. 1M Na2COs (10.9 mL, 10.9 mmol) was added dropwise, via syringe, and the resulting mixture stirred vigorously at 80°C for approximately 6h.

After cooling to ambient temperature, the rection mixture was diluted with ethyl acetate and filtered through celite'-Rj washing copiously with ethyl acetate. The filtrate was poured into water and the organic phase separated. The aqueous phase was re-extracted with ethyl acetate (x2), the combine organic extract washed with brine, dried (MgSO4) and concentrated i772 vacuo. The residue was purifie by flash chromatography

on silica gel (gradient elution; 70-85% ethyl acetate/hexanes as eluent) to give the title compound as a pale yellow foam (2.40 g, 100%).

Step MM: (S)-1-(2-Azabicyclo [2.2.2] oct-2-yl)-2-{3-(2-benzyloxy-1- methylethyl)-2-(3, 5-dimethylphenyl)-lH-(tert-butoxy- carbonyl)pyrrolo[2,3-c]pyridin-5-yl}-2-methylpropan-1-one Di-tert-butyl-dicarbonate (1.43 g, 4.37 mmol) was added to stirred suspension of (S)-1-(2-azabicyclo [2.2.2] oct-2-yl)-2- [3- (2-benzyloxy- 1-methyl-ethyl)-2-(3, 5-dimethylphenyl)-lH-pyrrolo(3, 5-dimethylphenyl)-lH-pyrrolo [2,3-c] pyridin-5-yl]-2- methylpropan-1-one (2.40 g, 4.37 mmol) and DMAP (0.053 g, 0.437 mmol) in dichloromethane (44 mL) at room temperature. After approximately lh, the rection mixture was poured into water and extracted with ethyl acetate (x3). The combine organic extract was washed with brine, dried (MgS04) and concentrated in vacuo. The residue was purifie by flash chromatography on silica gel (gradient elution; 35-45% ethyl acetate/ hexanes as eluent) to give the title compound as a colorless foam (2.54 g, 90%).

Step NN: (S)-1- [2-(2-Azabicyclo [2.2.2] oct-2-yl)]-2- {2- (3,5-dimethyl- phenyl)-3- (2-hydroxy-1-methylethyl)-lH- (tert-butoxy- carbonyl)pyrrolo[2,3-c]pyridin-5-yl}-2-methylpropan-1-one A mixture of (S)-1-(2-azabicyclo [2.2. 2]oct-2-yl)-2-{3-(2- benzyloxy-1-methylethyl)-2-(3,5-dimethylphenyl)-1H-(tert-but oxy- carbonyl) pyrrolo [2,3-c] pyridin-5-yl}-2-methylpropan-1-one (1.94 g, 2.99 mmol) and Pd (OH) 2 (Pd-20%; 100 mg) in glacial acetic acid/EtOH (1: 3; 20 mL) was hydrogenated at 50 psi for 4d. The resulting mixture was filtered through celite# washing copiously with EtOH, the filtrate evaporated i71 uacuo and the residue purifie by flash chromatography on silica gel (80% ethyl acetate/hexanes) to give the title compound as a colorless foam (1.32 g, 79%).

Step OO : (S)-1- (2-Azabicyclo [2.2.2] oct-2-yl)-2-{3- (2-azido-1-methyl- ethyl)-2- (3,5-dimethylphenyl)-lH-(tert-butoxycarbonyl)- pvrrolo (2, 3-cpvridin-5-vll-2-methylpropan-1-one

DEAD (0.38 mL, 2.42 mmol) was added dropwise, via syringe, to a stirred solution of (S)-1- [2- (2-azabicyclo [2.2.2] oct-2-yl)]-2- {2- (3, 5-dimethylphenyl)-3- (2-hydroxy-1-methylethyl)-1H (tert-butoxy- carbonyl) pyrrolo- [2,3-c] pyridin-5-yl}-2-methylpropan-1-one (0.338 g, 0.604 mmol), ZnN6#2py (0. 372 g, 1.21 mmol), PPh3 (0. 634 g, 2.42 mmol) and imidazole (0.164 g, 2.42 mmol) in CH2Cl2 (6 mL) at approximately 0°C.

After allowing to warm to ambient temperature overnight, the rection mixture was filtered through celiez washing copiously with dichloromethane, and then concentrated in vacuo. The residue was partially purifie by flash chromatography on silica gel (gradient elution; 50-60% ethyl acetate/hexanes as eluent) to give a mixture of the title compound contaminated with 1,2-dicarbethoxyhydrazine as a colourless solid.

Step PP: (S)-2-{3-(2-Amino-1-methylethyl)-2-(3, 5-dimethylphenyl)- IH- (tert-butoxycarbonyl) pyrrolo [2,3-c] pyridin-5-yl}-1-(2- azabicyclo [2.2.2] oct-2-vl)-2-methylpropan-1-one A mixture of crude (S)-l- (2-azabicyclo [2.2. 2]oct-2-yl)-2-{3-(2- azido-l-methylethyl)-2- (3, 5-dimethylphenyl)-IH- (tert-butoxycarbonyl)- pyrrolo [2, 3-c]-pyridin-5-yl}-2-methylpropan-1-one (0.604 mmol) and Pd/C (Pd-10%; 40 mg) in MeOH (6 mL) was hydrogenated at 50 psi for approximately 1h. The resulting mixture was filtered through celte*' washing copiously with methanol, the filtrate evaporated ia vacuo and the residue purifie by preparative thin layer chromatography on silica gel (double elution; 100% ethyl acetate as eluent) to give the title compound as a colorless foam (0.265 g, 78% overall).

Step QQ: (S)-1- (2-Azabicyclo [2.2.2] oct-2-yl)-2-{2- (3,5-dimethylphenyl)- 3-2-(2,4-dinitrobenzenesulfonylamino)-1-methylethyl]-1H- (tert-butoxycarbonyl) pyrrolo [2,3-c] pyridin-5-yl}-2-methyl- propan-1-one 2,4-Dinitrobenzenesulfonyl chloride (152 mg, 0.569 mmol) was added portionwise, to a vigorously stirred mulsion of (S)-2-{3-(2- amino-1-methylethyl)-2-(3,5-dimethylphenyl)-1H-(tert-butoxyc arbonyl)

pyrrolo [2,3-c] pyridin-5-yl}-1- (2-azabicyclo- [2.2.2] oct-2-yl)-2-methylpropan- 1-one (264 mg, 0.474 mmol) in saturated aqueous NaHCO3/ CH2Cl2 (1: 1; 4 mL) at approximately 0°C. After 10 min., the rection mixture was poured into water and extracted with ethyl acetate (x3). The combine organic extract was washed with brine, dried (MgS04) and concentrated in vacuo. The residue was purifie by flash chromatography on silica gel (gradient elution; 40-60% ethyl acetate/hexanes as eluent) to give the title compound as a yellow foam (299 mg, 80%).

4-2-Hydroxyethyl)-2-methylpyridin-1-oxide Step AAA (2-methylpyridin-4-yl) acetic acid methyl ester (and bis- adduct) A solution of 2,4-lutidine (10.4mL in 10mL dry tetrahydrofuran was added dropwise over 30 minutes to a freshly prepared solution of lithium diisopropylamide (lOOmmol in 60mL dry tetrahydrofuran) at room temperature. After 4 hours, a solution of dimethylcarbonate (7.6mL in 8mL dry tetrahydrofuran) was added and the mixture stirred at room temperature. After 16 hours, the rection was quenched by the addition of saturated aqueous ammonium chloride and extracted with ethyl acetate. The combine organics were washed with brine and dried over sodium sulfate. Purification of the concentrate by flash chromatography on silica gel (ethyl acetate: hexane, 2: 1) gave the title compound (4.2g).

Step BBB: (2-methylpyridin-4-yl)-acetic acid hydrochloride A solution of 2-methylpyridin-4-yl) acetic acid methyl ester and (bis) adduct (2. Og in 10mL concentrated hydrochloric acid) was heated to reflux on an oil bath. After 1 hour the mixture was cooled to room temperature, diluted with toluene and concentrated in vacuo to provide the crude title compound (1.67g).

Step CCC: ethylesteracid To a solution of (2-methylpyridin-4-yl) acetic acid (10g in 50mL ethanol) was added 0.50mL concentrated sulfuric acid and the mixture heated to reflux on an oil bath. After 3 hours, the mixture was cooled to room temperature and concentrated in vacuo. The residue was solvate in water and neutralized by the addition of 2N ammonium hydroxide. The mixture was then extracted with ethyl acetate, washed with brine and dried over sodium sulfate. Concentration in vacuo provided the crude title compound as a light brown oil (8.94g).

Step DDD: 2-(2-methylpyridin-4-vl)-ethanol To a solution of (2-methylpyridin-4-yl)-acetic acid ethyl ester (8.9g in 50mL dry tetrahydrofuran) at 0°C was added lithium aluminum hydride (50mL of a 1M solution in tetrahydrofuran) and the mixture stirred at low temperature. After 30 minutes, the rection was quenched by the sequential addition of 1.85mL water, 1.39mL 5N sodium hydroxide and 5.55mL water. After 10 minutes, the mixture was filtered through diatomaceous earth and the filtrate extracted with ether. The combine organics were concentrated in uacuo to give the crude title compound as a brown oil (5.0g).

Step EEE: 4-(2-hydroxYethyl)-2-methYlpvridin-1-oxide To a solution of 2- (2-methylpyridin-4-yl)-ethanol (1.5g in 6mL acetic acid) was added 4.2mL of a 30% solution of hydrogen peroxide and the mixture heated to 80°C on an oil bath. Cafter 7 hours, the mixture was cooled to room temperature and concentrated in vacuo. The residue was resolvated in methylene chloride and the excess acetic acid quenched by the careful addition of solid sodium carbonate. The mixture was then filtered and the residue washed with ethyl acetate then methylene chloride: methanol (3: 1). Purification of the concentrated filtrate by flash chromatography on silica gel (methylene chloride: methanol, 95: 5, then 90: 10) gave the title compound as a colorless oil (1.2g). MS ESI + f, llMS m/z 154.2 IH NMR (500 MHz, CD30D) 6 2.46 (s, 3H), 2.79 (t, J = 6.18 Hz, 5.95 Hz, 2H), 3.87 (t, J = 5.95Hz, 6.18Hz, 2H), 7.00 (m, 1H), 7.13 (s, 1H), 8.08 (d, J = 6.64Hz, 1H).